Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., and BOSTON -- July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc.

Recommendations from the Nation’s Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company BOSTON --(BUSINESS WIRE)--Jul. 20, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”)

BOSTON --(BUSINESS WIRE)--May 17, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023 , the Company received a written notification from the Listing

-- Q1 2023 net sales of $15.6 million , an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc. , delivering value to stakeholders in an all stock and contingent value rights (CVR) transaction -- -- Transaction expected to close in Q3 2023 -- BOSTON

  Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel

-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- BOSTON --(BUSINESS WIRE)--Mar. 22, 2023-- Spectrum Pharmaceuticals, Inc.

BOSTON --(BUSINESS WIRE)--Mar. 17, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a

BOSTON --(BUSINESS WIRE)--Feb. 8, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S.

-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -- BOSTON --(BUSINESS WIRE)--Jan. 31, 2023-- Spectrum Pharmaceuticals, Inc.

-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant -- BOSTON --(BUSINESS WIRE)--Jan. 26, 2023-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and

BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel , M.D., Executive Vice President and Chief Medical Officer, will step down from his role to

-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 27, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and

BOSTON --(BUSINESS WIRE)--Dec. 6, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care

-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and

— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities — BOSTON --(BUSINESS WIRE)--Nov.

-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Spectrum Pharmaceuticals, Inc.

BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update

-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- BOSTON --(BUSINESS WIRE)--Oct. 21, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies,

-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- BOSTON --(BUSINESS WIRE)--Sep. 23, 2022-- Spectrum Pharmaceuticals, Inc.

BOSTON --(BUSINESS WIRE)--Sep. 22, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee